John L Lucas

US Patent:

6867189, Mar 15, 2005

Filed:

Jul 22, 2002

Appl. No.:

10/202676

Inventors:

John Lucas - San Diego CA, US
Kristen Briggs - Del Mar CA, US

Assignee:

Genset S.A.

International Classification:

A61K038/17

US Classification:

514 12, 435 691, 4353201, 530324

Abstract:

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. Adipsin polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, insulin resistance, diabetes, and hypertension.

US Patent:

7459433, Dec 2, 2008

Filed:

May 26, 2003

Appl. No.:

10/515033

Inventors:

John Lucas - San Diego CA, US
Jiunn-chern Yeh - La Jolla CA, US
Deno Dialynas - San Diego CA, US

Assignee:

Serono Genetics Institute, S.A. - Evry

International Classification:

C07K 14/00
A61K 38/00

US Classification:

514 12, 514 2, 530350, 424 91

Abstract:

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of OBG3 polypeptide fragment comprising globular domain and all or part of OBG3 collagen-like region, has been identified that has utility for reducing body mass, for maintaining weight loss, and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

US Patent:

20050288223, Dec 29, 2005

Filed:

May 7, 2003

Appl. No.:

10/514040

Inventors:

John Lucas - San Diego CA, US
Deno Dialynas - San Diego CA, US

Assignee:

Genset S.A. - Evry

International Classification:

A61K038/17
C07K014/705

US Classification:

514012000, 530350000, 435069100, 435320100, 435325000, 536023500

Abstract:

The present invention relates to the field of obesity research. Fragments of OBG3 have been identified that reduce weight gain in animals. These fragments of OBG3 should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

US Patent:

20060089311, Apr 27, 2006

Filed:

Oct 3, 2002

Appl. No.:

10/496758

Inventors:

Aaron Scalia - La Jolla CA, US
John Lucas - Concord MA, US
Kristen Briggs - Del Mar CA, US

International Classification:

A61K 38/06

US Classification:

514018000

Abstract:

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of RYZN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

US Patent:

20060178354, Aug 10, 2006

Filed:

Feb 19, 2004

Appl. No.:

10/546882

Inventors:

John Lucas - San Diego CA, US

International Classification:

A61K 31/57

US Classification:

514178000

Abstract:

The invention relates to the treatment of chronic pain using DHEA or derivatives thereof either alone or in combination with at least one other drug. The invention also includes compositions comprising DHEA or a derivative thereof and a second drug.

US Patent:

20060258567, Nov 16, 2006

Filed:

Mar 26, 2003

Appl. No.:

10/510002

Inventors:

Kristen Briggs - Del Mar CA, US
Deno Dialynas - San Diego CA, US
John Lucas - Concord MA, US
Aaron Scalia - La Jolla CA, US

Assignee:

SERONO GENETICS INSTITITE S.A. - ENVRY

International Classification:

A61K 48/00
A61K 38/17

US Classification:

514008000, 514044000

Abstract:

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. XCRF polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

US Patent:

20060293225, Dec 28, 2006

Filed:

Jul 25, 2002

Appl. No.:

10/484707

Inventors:

Deno Dialynas - San Diego CA, US
John Lucas - Concord MA, US
Aaron Scalia - La Jolla, FR
Hiroaki Tanaka - Antony, FR

Assignee:

GENSET S.A. - Evry

International Classification:

A61K 38/17

US Classification:

514012000

Abstract:

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of GMG-2 polypeptide fragment comprising globular domain and all or part of GMG-2 collagen-like region, has been identified that has utility for reducing body mass, for maintaining weight loss, and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

US Patent:

20070129291, Jun 7, 2007

Filed:

Jul 30, 2002

Appl. No.:

10/480699

Inventors:

John Lucas - San Diego CA, US
Deno Dialynas - San Diego CA, US
Kristen Briggs - Del Mar CA, US

Assignee:

Genset S.A. - Evry

International Classification:

A61K 38/22

US Classification:

514012000

Abstract:

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of GENOBIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.